Amgen Finally Scores a Win In Its Big Copycat Drug Battle With Novartis
Fortune / Posted 5 days ago
3 related stories
have rejected one of its experimental drugs, a copycat version of Amgen’s amgn cancer patient white blood cell-booster Neulasta.
The Food and Drug Administration’s (FDA) rejection of Novartis’ biosimilar therapy is welcome news for Amgen,... Read more